Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent.
Axovant Sciences Ltd's shares plunged nearly 50 percent on Monday after the company scrapped its lead experimental dementia treatment following back-to-back trial failures.
Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday.
Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million (£628.8 million) to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.
The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday.
Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.
Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.
AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon's possible entry into the industry.
Allergan Plc on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis. | Video
Endo International Plc on Monday gave a glimpse of a quarter that could help ease investor concerns when it announced preliminary earnings well above market estimates, sending the generic-drug maker's shares up as much as 18 percent.
- Gold: PRECIOUS-Gold up, dollar shaken by U.S. government shutdown fears
- Oil Report: UPDATE 3- South Africa's ANC to force Zuma to quit as president -reports
- British Pound Report: UPDATE 3-Sterling falls after weak retail sales numbers dent optimism
- US Dollar Report: FOREX-U.S. shutdown fears pressure dollar, mark worst run since 2015